New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat;  ; conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core);   - modified release tablet - 0.45mg/20mg - active: bazedoxifene acetate 22.56mg equivalent to 20mg bazedoxifene - in tablet subcoat   conjugated estrogens 0.45mg (10.4895 mg conjugated estrogens (ce) dessication with lactose (containing 4.29% ce) - in tablet core)   excipient: ascorbic acid hyprolose hypromellose     isopropyl alcohol lactose monohydrate macrogol 400 magnesium stearate microcrystalline cellulose   opacode black ns-78-17821 opadry pink 03b14899 opaglos clear 98z19173 purified water     sucrose   sucrose palmitate - duavive is indicated for treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. the experience treating women older than 65 years is limited.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - powder for injection - 1 mg - active: indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - indomethacin is indicated for the closure of patent ductus arteriosus in premature babies. clear-cut clinical evidence of a haemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray. indomethacin should only be used in a hospital under supervision of a specialist neonatologist.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - powder for injection - 1 mg - active: indometacin sodium trihydrate 1.061mg equivalent to indomethacin 1 mg - indomethacin is indicated for the closure of patent ductus arteriosus in premature babies. clear-cut clinical evidence of a haemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly and pulmonary plethora on chest x-ray. indomethacin should only be used in a hospital under supervision of a specialist neonatologist.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - sunitinib malate 50.1mg equivalent to 37.5mg sunitinib;   - capsule - 37.5 mg - active: sunitinib malate 50.1mg equivalent to 37.5mg sunitinib   excipient: croscarmellose sodium gelatin ink iron oxide yellow magnesium stearate mannitol povidone sodium laurilsulfate titanium dioxide - sutent is indicated for the treatment of advanced renal cell carcinoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - aspirin 100mg (2 x 50mg);  ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin));  ; ramipril 10mg;   - combination capsule - 100mg/20mg/10mg - active: aspirin 100mg (2 x 50mg)   excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin))   excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 10mg   excipient: hypromellose microcrystalline cellulose opadry yellow sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide red titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - aspirin 100mg (2 x 50mg);  ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin));  ; ramipril 2.5mg;   - combination capsule - 100mg/20mg/2.5mg - active: aspirin 100mg (2 x 50mg)   excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin))   excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 2.5mg   excipient: hypromellose microcrystalline cellulose opadry yellow 80w32039 sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide black titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses

New Zealand - English - Medsafe (Medicines Safety Authority)

te arai biofarma limited - aspirin 100mg (2 x 50mg);  ; atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin));  ; ramipril 5mg;   - combination capsule - 100mg/20mg/5mg - active: aspirin 100mg (2 x 50mg)   excipient: microcrystalline cellulose opadry white oy-b-28920 amb purified talc sodium starch glycolate active: atorvastatin calcium trihydrate 21.69mg (2 x 10.845mg (equivalent to 20mg atorvastatin))   excipient: calcium carbonate colloidal silicon dioxide crospovidone hyprolose lactose monohydrate magnesium stearate opadry green 06o21881 polysorbate 80 pregelatinised maize starch active: ramipril 5mg   excipient: hypromellose microcrystalline cellulose opadry yellow sodium stearyl fumarate starch black ink (trinomia) gelatin iron oxide black iron oxide red titanium dioxide - trinomia is indicated for the secondary prevention of cardiovascular accidents as substitution therapy in adult patients adequately controlled with the mono-components given concomitantly at equivalent therapeutical doses

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - sucroferric oxyhydroxide, quantity: 2500 mg - tablet, chewable - excipient ingredients: colloidal anhydrous silica; neohesperidin-dihydrochalcone; magnesium stearate; flavour - velphoro is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease (ckd) on dialysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - sucroferric oxyhydroxide, quantity: 2500 mg - tablet, chewable - excipient ingredients: colloidal anhydrous silica; neohesperidin-dihydrochalcone; magnesium stearate; flavour - velphoro is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease (ckd) on dialysis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - alendronate sodium trihydrate, quantity: 91.35 mg (equivalent: alendronic acid, qty 70 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; mannitol; microcrystalline cellulose - treatment of osteoporosis. osteoporosis must be confirmed by the finding of low bone mass of at least two standard deviations below the gender specific mean for young adults, or by the presence of osteoporotic fracture.